Drug profile · INN
olsalazine sodium
DIPENTUM
olsalazine sodium (DIPENTUM) is a arachidonate 5-lipoxygenase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — olsalazine sodium
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
olsalazine sodium (DIPENTUM) is a arachidonate 5-lipoxygenase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Arachidonate 5-lipoxygenase inhibitor
Primary target: Polyunsaturated fatty acid 5-lipoxygenase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is olsalazine sodium?
olsalazine sodium (DIPENTUM) is a arachidonate 5-lipoxygenase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for olsalazine sodium?
DIPENTUM is a marketed brand name for olsalazine sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of olsalazine sodium?
olsalazine sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.